Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-L02 fixed-dose combination bioequivalence study in healthy volunteers
NCT07128654Phase 1Completed
- Sponsor
- Celltrion
- Start
- Sep 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CT-L02 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Celltrion. Primary endpoints: Area Under the Plasma Concentration-Time Curve at 72 hours and Peak Plasma Concentration at 72 hours. Started Sep 2025; status: completed.
02
Drugs
CT-L02
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07128654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128654.